Starpharma - Prostate Cancer Drug Cabazitaxel

The advantages* of DEP® cabazitaxel include:

• Improved side effect profile
• Detergent-free formulation
• No steroid pre-treatment
• Tumour-targeting
• Improved efficacy

DEP® cabazitaxel has patent filings to 2039 (plus up to an additional ~5 years). 

*Multiple preclinical studies have established improved efficacy, survival, and safety with DEP® with many different drugs.

DEP® cabazitaxel phase 2 program is well advanced. The program is an open-label trial, with the objective of establishing anti-tumour activity (efficacy) & safety.

Encouraging efficacy signals have been observed, including radiological responses, significant target tumour shrinkage and substantial tumour biomarker reductions (e.g. Prostate Specific Antigen - PSA), in cancers including prostate, ovarian, lung, gastroesophageal, head and neck, and other cancers.

DEP® cabazitaxel – phase 2 prostate cancer patients

• 25 heavily pre-treated patients (average age 73 years) with Stage (IV) hormone-refractory prostate cancer
• Average of 4 prior anti-cancer treatments and >70 cycles/months
• >95% had received prior taxanes, including docetaxel and cabazitaxel (Jevtana®)
• Patients received DEP® cabazitaxel at a dose of 20mg/m2 cabazitaxel
• No need for prophylactic steroids or antihistamines as polysorbate 80-free aqueous formulation
• No primary G-CSF4 prophylaxis required

DEP® cabazitaxel – phase 2 interim results in prostate cancer cohort^

100% of evaluable patients2 had one or more efficacy response:

• 64% had prolonged disease control for up to 36 weeks
• 18% had significant tumour shrinkage, a Partial Response (Jevtana® – 18.5%)
• 90% had a PSA decrease
• 52% had a ≥50% decrease in PSA (Jevtana® – 29.5%)
• 83% had no progression of secondary bone disease
• 56% evaluable for all three of these measures had responses in all three